Pembrolizumab plus chemotherapy for advanced gastric cancer – Authors' reply

The letter from Chen-yu Huang and Xiao-bing Wu raises questions pertaining to the survival results from the recent analysis of the KEYNOTE-859 study published in The Lancet Oncology.1 The authors suggest that the efficacy of addition of pembrolizumab to chemotherapy versus placebo plus chemotherapy might be affected by the choice of chemotherapy, type of post-discontinuation anticancer therapy, and the level of expression of PD-L1.